Amicus Therapeutics (FOLD) Q3 results: Revenues: $48.8M (+136.9%).
Net loss: ($61.8M) (+61.2%); loss/share: ($0.24) (+71.4%); Quick Assets: $514.2M (+2.0%).
2019 guidance: Galafold revenue: $170M – 180M from $160M – 180M.
Key Strategic Priorities: Complete enrollment in Phase 3 PROPEL clinical study in Pompe disease and report additional Phase 2 data.
Report additional two-year results from Phase 1/2 clinical study in CLN6 Batten disease and complete enrollment in ongoing CLN3 Batten disease Phase 1/2 study.
Shares are up 6% premarket.
Previously: Amicus Therapeutics EPS beats by $0.08, beats on revenue (Nov. 11)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.